Potential Benefit of Rituximab in Rhupus Patients From a Single-Center: A Series of 16 Cases

Conclusions In rhupus refractory to conventional treatment, T or B lymphocytes targeted therapies, and particularly rituximab, seem to be a relevant therapeutic option unlike anticytokine biologics.
Source: JCR: Journal of Clinical Rheumatology - Category: Rheumatology Tags: Concise Report Source Type: research